Ahead of print

Original article

Transfoveal Subthreshold Laser for the Treatment of Central Serous Chorioretinopathy: Efficacy and Safety According to Titrated-Fluence

Full Text links

Summary

Aim: To evaluate the anatomical and functional outcomes of titrated-fluence-based, transfoveal subthreshold micropulse laser in patients with acute and chronic central serous chorioretinopathy (CSC).

Materials and Methods: Secondary data from patients with acute or chronic CSC treated between June 2021 and December 2024 were analyzed. All patients underwent transfoveal 577-nm subthreshold micropulse titrated-fluence-based laser. Optical coherence tomography (OCT) was performed at baseline, 4 weeks post-treatment, and at 6 months. The primary outcome was subretinal fluid (SRF) resolution after the first laser session. Secondary outcomes included best-corrected visual acuity (BCVA), final SRF resolution rate, recurrence, and treatment-related adverse effects.

Results: Twenty eyes of 18 patients were included. Median fluence ranged from 16.98–33.95 J/cm² (median 22.64 J/cm²), with a median number of 343 spots (206–568 interquartile range). Complete SRF resolution after the first session occurred in 75% of eyes; final resorption was achieved in 80% with a statistically significant difference between the acute and chronic groups at 6 months (p = 0.007). Median BCVA improved from 0.3 logMAR at baseline to 0.2 logMAR at 4 weeks and remained stable at 0.2 logMAR at the final follow-up (p = 0.027). No adverse effects were observed.

Conclusion: Transfoveal subthreshold micropulse laser appears to be a safe and effective treatment modality for acute and chronic CSC. Fluence titration may contribute to improved clinical outcomes and may assist in optimizing treatment parameters.

References

  1. Van Dijk E, Boon C. Serous business: delineating the broad spectrum of diseases with subretinal fluid in the macula. Prog Retin Eye Res. 2021;84:100955. https://doi.org/10.1016/j.preteyeres.2021.100955
  2. Li X, Long H, Hu Q. Efficacy of subthreshold micropulse laser for chronic central serous chorioretinopathy: a meta-analysis. Photodiagnosis Photodyn Ther. 2022;39:102931. https://doi. org/10.1016/j.pdpdt.2022.102931
  3. Kiraly P, Habjan M, Smrekar J, Mekjavić P. Functional outcomes and safety profile of transfoveal subthreshold micropulse laser in persistent central serous chorioretinopathy. Life (Basel). 2023;13(5):1194. https://doi.org/10.3390/life13051194
  4. Arora S, Sridharan P, Arora T, Chhabra M, Ghosh B. Subthreshold diode micropulse laser versus observation in acute central serous chorioretinopathy. Clin Exp Optom. 2019;102(1):79-85. https://doi. org/10.1111/cxo.12818
  5. Long H, Liu M, Hu Q, Li X. 577-nm subthreshold micropulse laser treatment for acute central serous chorioretinopathy: a comparative study. BMC Ophthalmol. 2022;22(1):105. https://doi. org/10.1186/s12886-022-02330-0
  6. Van Dijk E, Fauser S, Breukink M, et al. Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in chronic central serous chorioretinopathy: the PLACE trial. Ophthalmology. 2018;125(10):1547-1555. https://doi. org/10.1016/j.ophtha.2018.04.021
  7. Robertson D, Ilstrup D. Direct, indirect, and sham laser photocoagulation in the management of central serous chorioretinopathy. Am J Ophthalmol. 1983;95(4):457-466. https://doi.org/ 10.1016/0002-9394(83)90265-9
  8. Bousquet E, Zhao M, Daruich A, Behar-Cohen F. Mineralocorticoid antagonists in the treatment of central serous chorioretinopathy. Exp Eye Res. 2019;187:107754. https://doi.org/10.1016/j.exer.2019.107754
  9. Scholz P, Altay L, Fauser S. A review of subthreshold micropulse laser for treatment of macular disorders. Adv Ther. 2017;34(7):1528- 1555. https://doi.org/10.1007/s12325-017-0559-y
  10. Van Rijssen T, van Dijk E, Yzer S, et al. Central serous chorioretinopathy: towards an evidence-based treatment guideline. Prog Retin Eye Res. 2019;73:100770. https://doi.org/10.1016/j.preteyeres.2019.07.003
  11. Lotery A, Sivaprasad S, O’Connell A, et al. Eplerenone for chronic central serous chorioretinopathy (VICI): a randomized controlled trial. Lancet. 2020;395(10220):294-303. https://doi.org/10.1016/S0140-6736(19)32981-2
  12. Chhablani J, Kalra G, Alkwatli L, et al. Safety of various parameter sets with navigated microsecond pulsing laser in central serous chorioretinopathy. Int J Retina Vitreous. 2021;7(1):62. https://doi. org/10.1186/s40942-021-00335-3
  13. Gawęcki M, Jaszczuk-Maciejewska A, Jurska-Jaśko A, Kneba M, Grzybowski A. Transfoveal micropulse laser treatment of central serous chorioretinopathy within six months of disease onset. J Clin Med. 2019;8(9):1398. https://doi.org/10.3390/jcm8091398
  14. Gawęcki M. Micropulse laser treatment of retinal diseases. J Clin Med. 2019;8(2):242. https://doi.org/10.3390/jcm8020242
  15. Keunen J, Battaglia-Parodi M, Vujosevic S, Luttrull J. International Retinal Laser Society guidelines for subthreshold laser treatment. Transl Vis Sci Technol. 2020;9(9):15. https://doi.org/10.1167/tvst.9.9.15
  16. Abd Elhamid A. Subthreshold micropulse yellow laser treatment for nonresolving central serous chorioretinopathy. Clin Ophthalmol. 2015;9:2277-2283. https://doi.org/10.2147/OPTH.S87499
  17. Zhang Z, Deng C, Duan J, et al. The role of en face imaging of retinal pigment epithelium alterations in rapid classification of central serous chorioretinopathy using widefield swept-source optical coherence tomography. Retina. 2026;46(2):373-382. https://doi. org/10.1097/IAE.0000000000004693
  18. Maltsev D, Kulikov A, Burnasheva M, Chhablani J. En face OCT trans­ illumination for evaluation of retinal pigment epithelium alteration in central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2022;260(7):2231-2237. https://doi.org/10.1007/s00417-021-05537-x
  19. Funatsu R, Mihara N, Miyake S, et al. Subretinal fluid duration and clinical outcomes in central serous chorioretinopathy: an analysis of time-to-photodynamic therapy. Am J Ophthalmol. 2026;283:7-13. doi: 10.1016/j.ajo.2025.11.039
  20. Lanzetta P, Furlan F, Morgante L, Veritti D, Bandello F. Nonvisible subthreshold micropulse diode laser treatment of central serous chorioretinopathy. Eur J Ophthalmol. 2008;18(6):934-940. https:// doi.org/10.1177/112067210801800613
  21. Chhablani J, SOLS Writing Committee. Subthreshold laser therapy guidelines for retinal diseases. Eye (Lond). 2022;36(12):2234-2235. https://doi.org/10.1038/s41433-022-02136-w